FindTrial
Sign In

Clinical trial for the efficacy and safety of platelet and TPO in the treatment for chronic liver disease

Clinical trial for the efficacy and safetyof platelet and TPO in the treatment in chronic hepatitis,cirrhosis and HCC patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019523
Enrollment
Unknown
Registered
2018-11-16
Start date
2016-09-30
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis, cirrhosis and HCC

Interventions

Platelet group:Platelet transfusion
TPO group:TPO subcutaneous injection

Sponsors

Affiliated Hospital of Jiangsu University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Clinic diagnose of chronic hepatitis and liver cirrhosis; 2. In patient; 3. 30,000 /µL< Platelets < 70,000 /µL; 4. Child-Pugh B 5. Aged 18-65 years; 6. Informed Consent.

Exclusion criteria

Exclusion criteria: 1. Acute hepatitis; 2. Liver function test a value for patients more than standard 5 times ,AST/ALT more than standard 3 times; 3. HIV; 4. Severe brain, heart head blood-vessel , respiratory system d, kidney disease, digestive system, merge blood system and neurological and psychiatric diseases history; 5. HbA1c> 8.0; 6. Pregnant, Plan to pregnant; 7. Oral medicine to improve the platelet count; 8. Platelet transfusion in 2 weeks; 9. ALB transfusion in 3 months; 10. Partial splenectomy or splenic artery embolization history.

Design outcomes

Primary

MeasureTime frame
ALB;Platelet;ChE;Liver Volume;—

Secondary

MeasureTime frame
liver function;PT;—

Countries

China

Contacts

Public ContactYu-Mei Li

Affiliated Hospital of Jiangsu University

yumeili@ujs.edu.cn+86 13914569541

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026